Advertisement
BCYC vs PCVX
Which Stock Would AI Choose? Bicycle Therapeutics (BCYC) vs. Vaxcyte (PCVX) Stock Comparison
Key Takeaways
- BCYC and PCVX are both clinical-stage biotech companies, but they operate in entirely different therapeutic areas — oncology versus infectious disease vaccines — leading to markedly different risk-reward profiles.
- Vaxcyte (PCVX) has delivered positive year-to-date and one-year returns, while Bicycle Therapeutics (BCYC) has experienced significant price erosion, trading near its 52-week low.
- PCVX commands a market cap of approximately $7.9 billion with a late-stage Phase 3 catalyst, whereas BCYC's market cap has contracted to roughly $300 million amid pipeline reprioritization.
- Both companies remain pre-revenue, but PCVX holds a much larger cash reserve (approximately $2.8 billion) compared to BCYC's roughly $628 million, extending its operational runway.
- Analyst consensus for both stocks is broadly "Hold," though price targets suggest substantially more perceived upside for BCYC from current levels given its deeply depressed valuation.
- Insider selling activity has been noted at both companies in recent weeks, primarily through pre-arranged Rule 10b5-1 trading plans.
Introduction
Biotechnology stocks represent some of the highest-risk, highest-reward opportunities in the equity market. Comparing two clinical-stage names — BCYC (Bicycle Therapeutics) and PCVX (Vaxcyte) — offers a useful lens into how market capitalization, pipeline maturity, cash runway, and sector dynamics can generate starkly different outcomes for investors. Bicycle Therapeutics is an oncology-focused platform company aiming to revolutionize targeted cancer therapy, while Vaxcyte is engineering next-generation pneumococcal conjugate vaccines. This comparison is particularly relevant for traders and investors seeking to understand relative positioning, momentum, and the types of catalysts that drive biotech valuations in the current market environment.
BCYC Overview and Recent Performance
BCYC, or Bicycle Therapeutics plc, is a clinical-stage biopharmaceutical company headquartered in Cambridge, United Kingdom. The company's proprietary Bicycle® platform produces fully synthetic, constrained peptide molecules designed to combine the targeting precision of biologics with the tissue-penetrating properties of small molecules. Its pipeline includes zelenectide pevedotin (a Bicycle Toxin Conjugate, or BTC, targeting Nectin-4), nuzefatide pevedotin (targeting EphA2), and BT7480 (a Bicycle Tumor-Targeted Immune Cell Agonist, or Bicycle TICA®). In recent months, BCYC's stock has been under considerable pressure, trading near $4 per share and down approximately 45% year-to-date. The company reported a wider-than-expected Q1 2026 loss of $0.87 per share on negligible revenue of roughly $0.9 million, missing analyst estimates on both counts. A major strategic pivot — including a 30% workforce reduction and the discontinuation of certain clinical trials — has refocused resources on next-generation programs. While the company held approximately $628 million in cash at the end of 2025, the elevated cash burn rate and uncertain timeline to pivotal data readouts have weighed heavily on sentiment.
PCVX Overview and Recent Performance
PCVX, or Vaxcyte, Inc., is a clinical-stage vaccine innovation company based in San Carlos, California. The company is developing high-fidelity vaccines using its XpressCF® cell-free protein synthesis platform. Its lead candidate, VAX-31, is a 31-valent pneumococcal conjugate vaccine (PCV) currently in a pivotal Phase 3 adult clinical program (the OPUS trial) and a Phase 2 infant study. VAX-31 is designed to be the broadest-spectrum PCV candidate in clinical development. In recent months, PCVX shares have traded in the mid-$50s range, with a year-to-date gain of approximately 18% and a one-year return exceeding 50%. The company reported a Q1 2026 loss of $2.30 per share, also missing consensus estimates, yet the stock has maintained relative stability thanks to its substantial cash position of approximately $2.8 billion, which management projects will fund operations through mid-2028. Recent milestones include the dosing of the first participant in the Phase 1 study of VAX-A1 (targeting Group A Streptococcus) and the appointment of Dr. Moncef Slaoui to the board of directors in June 2026.
Trending AI Robots
In a market environment where biotech swings can be swift and severe, AI-driven trading tools are increasingly relevant for active traders. Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots, chosen from hundreds of available bots that collectively trade thousands of different tickers. These bots employ diverse trading styles, strategies, and timeframes — from 5-minute and 15-minute intraday agents to 60-minute swing trading models. Performance metrics vary widely, with some bots posting annualized returns in excess of 70% and win rates above 65%, while others focus on capital preservation with lower volatility profiles. Each bot's statistics, including profit factor (the ratio of gross profit to gross loss, where values above 2.0 are considered strong), Sharpe ratio (a measure of risk-adjusted return), and trade frequency, are fully transparent on the platform. For traders looking to navigate the volatility inherent in names like BCYC and PCVX, exploring the Trending AI Robots section can offer data-driven decision support.
Head-to-Head Comparison
The contrast between BCYC and PCVX is instructive across several dimensions. In terms of business model, BCYC is an oncology platform company whose value hinges on demonstrating that its Bicycle molecules can effectively target historically difficult-to-drug cancer antigens. PCVX, by contrast, is developing vaccines against well-characterized bacterial pathogens — a field with established regulatory pathways and known market demand, dominated by players like Pfizer's Prevnar franchise. Regarding pipeline maturity, PCVX's VAX-31 is already in Phase 3, placing it closer to a potential regulatory submission, while BCYC's lead programs are in earlier-stage trials with key data readouts still ahead. On the financial side, both are cash-burning, pre-revenue biotechs, but PCVX's $2.8 billion balance sheet dwarfs BCYC's roughly $628 million, giving Vaxcyte a considerably longer runway without dilution risk. Market sentiment diverges sharply: PCVX has benefited from momentum and a narrative of category-defining vaccine breadth, while BCYC has been weighed down by pipeline prioritization, missed earnings, and a declining stock price. Risk factors for PCVX center on clinical trial outcomes and competitive dynamics in the pneumococcal vaccine market; for BCYC, the primary risks include platform validation, financing needs, and execution on a narrowed pipeline. In essence, PCVX represents a later-stage, higher-visibility bet on vaccine innovation, whereas BCYC is an earlier-stage wager on a novel therapeutic modality with a deeply discounted valuation.
Tickeron AI Verdict
Based on observable trend consistency, relative financial stability, and near-term catalyst visibility, Tickeron's AI-driven analysis would likely favor PCVX in the current environment. Vaxcyte's positive price momentum, substantially larger cash reserves, and a Phase 3-stage lead program provide a more stable foundation for trend-following algorithms than the deeply oversold but uncertain recovery path facing BCYC. That said, BCYC's severely compressed valuation — trading at a steep discount to its average analyst price target — may present a probabilistic opportunity for mean-reversion strategies, particularly if upcoming clinical data catalyze a sentiment shift. Ultimately, the AI's preference is not a definitive prediction but a reflection of where momentum, risk-adjusted positioning, and catalyst clarity appear to converge at this moment in time.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Hold and PCVX is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BCYC’s FA Score shows that 1 FA rating(s) are green whilePCVX’s FA Score has 0 green FA rating(s).
- BCYC’s FA Score: 1 green, 4 red.
- PCVX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BCYC’s TA Score shows that 3 TA indicator(s) are bullish while PCVX’s TA Score has 5 bullish TA indicator(s).
- BCYC’s TA Score: 3 bullish, 5 bearish.
- PCVX’s TA Score: 5 bullish, 4 bearish.
Price Growth
BCYC (@Biotechnology) experienced а -0.26% price change this week, while PCVX (@Biotechnology) price change was -1.06% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.22%. For the same industry, the average monthly price growth was -8.12%, and the average quarterly price growth was +2790.29%.
Reported Earning Dates
BCYC is expected to report earnings on Aug 06, 2026.
PCVX is expected to report earnings on Aug 12, 2026.
Industries' Descriptions
@Biotechnology (-1.22% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BCYC | PCVX | BCYC / PCVX | |
| Capitalization | 269M | 7.81B | 3% |
| EBITDA | -183.2M | -1.06B | 17% |
| Gain YTD | -45.480 | 17.209 | -264% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 61.2M | 0 | - |
| Total Cash | 510M | 1.74B | 29% |
| Total Debt | 14.7M | 116M | 13% |
BCYC | PCVX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 66 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 77 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 80 | 48 | |
P/E GROWTH RATING 1..100 | 100 | 47 | |
SEASONALITY SCORE 1..100 | 65 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BCYC's Valuation (9) in the null industry is somewhat better than the same rating for PCVX (66). This means that BCYC’s stock grew somewhat faster than PCVX’s over the last 12 months.
PCVX's Profit vs Risk Rating (77) in the null industry is in the same range as BCYC (100). This means that PCVX’s stock grew similarly to BCYC’s over the last 12 months.
PCVX's SMR Rating (98) in the null industry is in the same range as BCYC (98). This means that PCVX’s stock grew similarly to BCYC’s over the last 12 months.
PCVX's Price Growth Rating (48) in the null industry is in the same range as BCYC (80). This means that PCVX’s stock grew similarly to BCYC’s over the last 12 months.
PCVX's P/E Growth Rating (47) in the null industry is somewhat better than the same rating for BCYC (100). This means that PCVX’s stock grew somewhat faster than BCYC’s over the last 12 months.
| BCYC | PCVX | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 86% | 3 days ago 76% |
| Stochastic ODDS (%) | 3 days ago 81% | 3 days ago 81% |
| Momentum ODDS (%) | 3 days ago 83% | 3 days ago 77% |
| MACD ODDS (%) | 3 days ago 90% | 3 days ago 74% |
| TrendWeek ODDS (%) | 3 days ago 88% | 3 days ago 73% |
| TrendMonth ODDS (%) | 3 days ago 87% | 3 days ago 75% |
| Advances ODDS (%) | N/A | N/A |
| Declines ODDS (%) | 5 days ago 89% | 5 days ago 71% |
| BollingerBands ODDS (%) | 3 days ago 84% | 3 days ago 86% |
| Aroon ODDS (%) | 3 days ago 84% | 3 days ago 80% |
Advertisement
BCYC and
Correlation & Price change
A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with DNLI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then DNLI could also see price increases.
| Ticker / NAME | Correlation To BCYC | 1D Price Change % | ||
|---|---|---|---|---|
| BCYC | 100% | -3.74% | ||
| DNLI - BCYC | 48% Loosely correlated | -5.46% | ||
| BHVN - BCYC | 47% Loosely correlated | -2.32% | ||
| BCAX - BCYC | 46% Loosely correlated | +3.16% | ||
| PCVX - BCYC | 46% Loosely correlated | -3.36% | ||
| MGTX - BCYC | 45% Loosely correlated | -1.59% | ||
More | ||||
PCVX and
Correlation & Price change
A.I.dvisor indicates that over the last year, PCVX has been loosely correlated with VIR. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if PCVX jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To PCVX | 1D Price Change % | ||
|---|---|---|---|---|
| PCVX | 100% | -3.36% | ||
| VIR - PCVX | 52% Loosely correlated | -2.70% | ||
| BCAX - PCVX | 47% Loosely correlated | +3.16% | ||
| DNLI - PCVX | 47% Loosely correlated | -5.46% | ||
| BCYC - PCVX | 47% Loosely correlated | -3.74% | ||
| KURA - PCVX | 47% Loosely correlated | -3.22% | ||
More | ||||